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 The survival of patients with small cell lung cancer (SCLC), which 
accounts for 15% – 20% of lung cancers, has improved only mar-
ginally in the past 25 years ( 1 ). Although patients initially respond 
to chemotherapy, the majority relapse and die from metastatic 
disease progression. 
 Several lines of evidence suggest that angiogenesis plays an impor-
tant role in this cancer in particular ( 2 ). Patients with SCLC express 
functional vascular endothelial growth factor receptor (VEGFR)-2 
and VEGFR-3 on their tumor cells ( 3 ) and have increased levels of 
serum vascular endothelial growth factor (VEGF) ( 4 ). Increased pre-
treatment levels of VEGF and basic ﬁ broblast growth factor are 
associated with poor response to chemotherapy and shorter survival 
( 5 – 7 ). SCLC is more vascularized than non – small cell lung cancer 
(NSCLC), as shown by a higher microvessel density ( 8 ). 
 It has been hypothesized that the addition of thalidomide — one 
of the ﬁ rst anti-angiogenic agents discovered ( 9 ) — to chemotherapy 
could improve survival in lung cancer patients because a beneﬁ t is 
seen in a variety of other cancers, particularly multiple myeloma 
( 10 – 14 ). Results from previously published small studies ( 15 – 17 ) in 
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 ARTICLE 
 Anti-angiogenic Therapy Using Thalidomide 
Combined With Chemotherapy in Small Cell Lung 
Cancer: A Randomized, Double-Blind, Placebo-
Controlled Trial 
 Siow Ming  Lee ,  Penella J.  Woll ,  Robin  Rudd ,  David  Ferry ,  Mary  O’Brien ,  Gary  Middleton ,  Stephen  Spiro , 
 Lindsay  James ,  Kulsam  Ali ,  Mark  Jitlal ,  Allan  Hackshaw 
  Background  Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a 
highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with che-
motherapy and as maintenance treatment. 
  Methods  A total of 724 patients (51% with limited and 49% with extensive disease) were randomly assigned to 
receive placebo or thalidomide capsules, 100 – 200 mg daily for up to 2 years. All patients received etopo-
side and carboplatin every 3 weeks for up to six cycles. Endpoints were overall survival, progression-free 
survival, tumor response rate, toxicity, and quality of life (QoL). Hazard ratios (HRs) for comparing thalido-
mide against placebo were estimated using Cox regression modeling. Statistical tests were two-sided. 
  Results  The median overall survival was 10.5 months (placebo) and 10.1 months (thalidomide) (HR for death = 
1.09, 95% confidence interval [CI] = 0.93 to 1.27;  P = .28). Among patients with limited-stage disease, there 
was no evidence of a survival difference (HR for death = 0.91, 95% CI = 0.73 to 1.15), but among patients 
with extensive disease, survival was worse in the thalidomide group (HR for death = 1.36, 95% CI = 1.10 
to 1.68). Progression-free survival rates were also similar in the two groups (HR = 1.07, 95% CI = 0.92 to 
1.24). Thalidomide was associated with an increased risk of having a thrombotic event, mainly pulmonary 
embolus and deep vein thrombosis (19% thalidomide vs 10% placebo; HR = 2.13, 95% CI = 1.41 to 3.20; 
 P < .001). There were no statistically significant differences between treatments in hematological and non-
hematological toxic effects, except more patients in the thalidomide group had rash, constipation, or 
neuropathy. Overall, QoL scores were similar in the two treatment groups, but thalidomide was associated 
with less insomnia and diarrhea and more constipation and peripheral neuropathy. 
  Conclusions  In this large randomized trial, thalidomide in combination with chemotherapy did not improve survival of 
patients with SCLC but was associated with an increased risk of thrombotic events. 
  J Natl Cancer Inst 2009;101: 1049 – 1057 
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which thalidomide was given concurrently with etoposide and car-
boplatin and was continued as maintenance therapy (including our 
phase II study in which the response rate was 68%) ( 17 ) suggest 
that thalidomide might be effective in the treatment of patients 
with SCLC. In the phase III trial reported here, we used continu-
ous low-dose thalidomide (200 mg) because two earlier studies 
( 15 , 18 ) demonstrated that this dose was well tolerated and associ-
ated with a survival that was greater than expected. Thalidomide 
was given concurrently with chemotherapy to decrease tumor vas-
cular permeability and interstitial ﬂ uid pressure and thus improve 
chemotherapy delivery ( 19 – 22 ). 
 In addition to its anticachexic and immunomodulatory effects 
( 23 – 25 ), thalidomide is postulated to have a synergistic effect with 
platinum-based chemotherapy ( 26 ). We used carboplatin instead 
of cisplatin in combination with etoposide because carboplatin is 
considerably less toxic (with regard to emesis, neurotoxicity, renal 
damage, and electrolyte imbalance) and can be given without spe-
cial hydration as an outpatient treatment and because studies show 
that carboplatin and etoposide have an activity that is similar to 
that of standard cisplatin and etoposide ( 27 , 28 ). 
 Patients and Methods 
 Study Design 
 We performed a randomized, phase III, double-blind, placebo-
controlled trial to determine whether thalidomide improves sur-
vival or quality of life (QoL) among SCLC patients receiving 
chemotherapy. Approvals from multicenter and local research eth-
ics were obtained for the trial. Written informed consent was 
obtained from all patients before study entry. 
 Patients 
 A total of 724 patients were recruited from 79 centers in the UK 
National Cancer Research Network (May 2003 to February 2006). 
Eligibility criteria included histologically or cytologically con-
firmed SCLC, no previous chemotherapy or radiotherapy, age 
greater than 18 years, Eastern Cooperative Oncology Group 
(ECOG) performance status 0 – 3, life expectancy greater than 
8 weeks, adequate renal function (EDTA clearance >60 mL/min or 
creatinine clearance >50 mL/min), and a negative pregnancy test. 
Patients with symptomatic brain metastases requiring immediate 
radiotherapy or with a previous malignancy during the 3 years 
previous to the diagnosis of SCLC (unless nonmelanoma skin 
cancer or early cervical cancer) were excluded. Follow-up contin-
ued until September 2008, when the database was closed for 
analysis. 
 Patients were randomly assigned to receive thalidomide or pla-
cebo after hospital staff telephoned the Cancer Research UK & 
University College London Cancer Trials Center. Trial center 
staff, clinicians, and patients were unaware of the allocation. 
Stratiﬁ ed randomization was used with a block size of 4, incorpo-
rating disease stage (limited or extensive disease), ECOG perfor-
mance status (0 or 1 vs 2 or 3), center, and alkaline phosphatase 
( ≤ 1.5 vs >1.5 × upper limit of normal) ( 29 ); ClinicalTrials.gov 
number: NCT00061919. 
 Trial Treatments 
 All patients were scheduled to receive etoposide (120 mg/m 2 intra-
venously on days 1 and 2 and 100 mg orally twice a day, or 120 mg/m 2 
intravenously on day 1 and 100 mg orally twice a day on days 2 and 
3) and carboplatin (area under the curve [AUC] = 5.0 intravenously 
on day 1 for patients with extensive-stage disease and AUC = 6.0 
intravenously on day 1 for patients with limited-stage disease) 
every 3 weeks for up to six cycles. Carboplatin dosage was deter-
mined using the Calvert formula. The chemotherapy agents were 
given at full dose every 3 weeks or delayed until hematological 
recovery following the previous cycle. Dose modifications (delays 
or reductions) were allowed if results of pretreatment blood tests 
(whole blood count <3 × 10 9 /L, absolute neutrophil count <1.5 × 
10 9 /L, or platelets <100 × 10 9 /L) and/or renal function tests indi-
cated that they were necessary. Thoracic radiotherapy (TRT) and 
prophylactic cranial irradiation (PCI) were given to patients with a 
complete or a partial response, according to local practice. The 
recommended doses were 40 Gy in 15 fractions for a period of 3 
weeks (for TRT) and 25 Gy in 10 fractions for a period of 2 weeks 
(for PCI) to begin approximately 3 weeks after the last cycle of 
chemotherapy. At the time the study was designed, it was not rou-
tine practice to treat limited-disease patients with early and con-
comitant radiotherapy because a UK trial ( 30 ) suggested no 
survival benefit in patients receiving early chemotherapy. All other 
comedications were given according to local practice. 
 Thalidomide or matching placebo capsules were taken orally 
once daily from the start of chemotherapy for 2 years. The starting 
dose was 100 mg/d; if this dose was well tolerated, it was increased 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Small cell lung cancer is very angiogenic, and thalidomide is an 
anti-angiogenic agent that has been used in combination with 
chemotherapy. 
 Study design 
 Randomized controlled trial of thalidomide vs placebo in 724 
patients with small cell lung cancer who were undergoing chemo-
therapy. Overall survival and toxic effects were compared overall 
and among patients with extensive vs limited disease. 
 Contribution 
 Median overall survival was similar in the two groups; in analysis 
by disease extent, patients with extensive disease who were 
treated with thalidomide had worse overall survival than those 
treated with placebo. Patients treated with thalidomide had higher 
risk of thrombotic events than patients treated with placebo. 
 Implications 
 Overall, among patients with small cell lung cancer in this study, 
treatment with thalidomide did not improve overall survival but 
increased the risk of having a thrombotic event. 
 Limitations 
 The dose of thalidomide given in this study was lower than that 
given in some previous studies. Because bone or brain scans are 
not routinely performed in the United Kingdom, results of analysis 
by disease extent may not be generalizable to other populations 
with more stringent criteria. 
 From the Editors 
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to 150 mg/d at the end of chemotherapy for 1 month and then to 
200 mg/d for the rest of the trial. The protocol speciﬁ ed that the 
dose could be either reduced or stopped (in practice, often tempo-
rarily) if the patient suffered symptoms including drowsiness, rash, 
sensory neuropathy, constipation, and dizziness. Strict verbal and 
written guidelines were given to patients regarding requirements 
for contraception and pregnancy testing. Women of childbearing 
potential were asked to abstain from heterosexual intercourse or to 
use two methods of contraception, and male patients engaging in 
intercourse with women of childbearing potential were asked to 
use barrier contraception. 
 Assessments 
 Initial assessment included physical examination, full blood count, 
serum chemistry (including tests for levels of creatinine, bilirubin, 
aspartate transaminase or alanine transaminase, alkaline phos-
phatase, lactate dehydrogenase, calcium, and albumin), chest 
X-ray, and computed tomography (CT) to the chest and upper 
abdomen to include the adrenal glands. Bone and brain scans were 
done only if clinically indicated (including elevated alkaline phos-
phatase, bony pain, or symptoms and signs of raised intracranial 
pressure). During chemotherapy, before each cycle, we repeated 
the physical and neurological examinations, hematology and 
chemistry tests, QoL questionnaires, and chest X-ray. Assessment 
CT scans were performed at cycle 3 and after the end of chemo-
therapy, and we recorded study drug compliance and toxicity. 
Neither the diagnostic pathology nor the radiological response was 
centrally reviewed. QoL assessments using the EORTC-QLQ 
C30 and lung cancer module (LC 14) ( 31 ) were made at the time 
of random assignment, during each chemotherapy cycle, at the end 
of chemotherapy, and then every 6 months until 24 months from 
the time of random assignment. During follow-up, assessments in 
the clinic were scheduled every 2 months after chemotherapy for 
the first 2 years and then for every 3 months. These assessments 
included a clinical and neurological examination; a chest X-ray; a 
CT scan of the chest, abdomen, and/or brain (when clinically indi-
cated with symptoms or signs suggesting disease progression); and 
an assessment of toxicity. Women of childbearing potential had a 
pregnancy test before starting the study drug, at the beginning of 
each chemotherapy cycle, and at every monthly visit after chemo-
therapy if still taking study drug. The database was closed for 
analysis in September 2008. 
 Statistical Analysis 
 The primary endpoint was overall survival measured from the date 
of random assignment until date of death or date last seen. 
Secondary endpoints were progression-free survival, tumor 
response rates (using the RECIST criteria), toxicity (using National 
Cancer Institute of Canada Common Toxicity Criteria, version 
2.0), and QoL. Analyses were by intention to treat (ie, according 
to the trial arm allocated to, and patients were included whether 
they took the study drug or not), unless otherwise specified. By 
this, we performed analyses according to the random allocation of 
treatment, regardless of what treatment patients actually received. 
Overall survival and progression-free interval were assessed by 
calculating the hazard ratio (HR) using Kaplan – Meier analysis and 
Cox regression modeling and by comparing thalidomide against 
placebo. For each specified adverse event, the maximum grade that 
the patient experienced during chemotherapy and follow-up was 
used, and the proportions were compared between the treatment 
groups. QoL measurements were examined using a repeated mea-
sures analysis allowing for baseline values (Proc Mixed in SAS). All 
statistical tests were two-sided, and  P less than .05 was considered 
statistically significant. 
 The target sample size was 720 patients. This was the number 
of patients required to detect a difference in the 2-year overall 
survival rate of 7 percentage points (from 12% placebo to 19% 
thalidomide) ( 32 ), with 85% power and 5% two-sided test of 
statistical signiﬁ cance (log-rank test). 
 Compliance to trial treatment was examined by calculating, for 
each patient, the time from random assignment until death or 
when the treatment was stopped early. This length of time was 
used to estimate the median time on the study drug in each trial 
arm. We also expressed the number of days when the patient was 
taking the study drug as a percentage of the total number of days 
spent in the study (ie, from time of random assignment until death 
or date last seen), to allow for those who temporarily stopped their 
study drug. For example, if a patient who was allocated to receive 
thalidomide was in the trial for 12 months (from time of random 
assignment until death) and during this time had stopped the drug 
for 3 months in total, the proportion of time spent on study drug 
was taken to be 75%. 
 Results 
 A total of 724 patients were randomly assigned to treatment: 359 
to placebo and 365 to thalidomide. Limited-stage disease was 
found in 51% of patients and extensive-stage disease was found in 
49%. The two groups were well balanced according to baseline 
characteristics ( Table 1 ). A similar proportion of patients with 
limited-stage disease in the thalidomide and placebo groups 
received chest radiotherapy (57% vs 53%) or PCI (44% vs 38%). 
 Treatment Administration 
 A total of 692 patients (96%) started placebo or thalidomide, 28 
did not start at all, and data were missing for four ( Figure 1 ). The 
median time (25th – 75th percentile) on the study drug was 7.9 
months (4.4 – 11.6 months) and 6.8 months (2.6 – 10.4 months) for 
placebo and thalidomide, respectively ( P = .03;  Figure 2 ). A total of 
76% of patients on placebo and 67% on thalidomide took their 
allocated treatment for at least half of the time they were in the 
study ( Supplementary  Figure  1 , available online). Among the 177 
patients with limited-stage disease in the thalidomide group, 101 
(57%) had thoracic radiotherapy and 77 (44%) had PCI; among 
the 191 patients in the placebo group, 102 (53%) had thoracic 
radiotherapy and 72 (38%) had PCI. 
 The study drug did not affect compliance to chemotherapy. 
The proportion of patients who completed all planned six chemo-
therapy cycles was similar between the placebo and the thalido-
mide groups — 61% (thalidomide) and 65% (placebo) ( see 
 Supplementary  Tables  1 and  2 , available online). The proportion 
of patients whose chemotherapy dose was delayed or reduced also 
did not differ between the groups. Chemotherapy dose delays 
occurred in 59% and 60% of patients and reductions occurred in 
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30% and 26% of patients during any cycle, in the thalidomide and 
placebo groups, respectively. Patients in the thalidomide group 
were more likely than patients in the placebo group to stop treat-
ment before cycle 6 because of toxicity (12% vs 7%). 
 Efficacy 
 The median follow-up was 37 months, and 649 patients had died 
(329 in the thalidomide group and 320 in the placebo group), 87% 
from progressive SCLC ( Supplementary  Table  3 , available online) 
at the end of follow-up. There was no evidence of an effect of 
thalidomide on either overall survival (unadjusted HR for death = 
1.09, 95% confidence interval [CI] = 0.93 to 1.27) or progression-
free survival ( Figure 3 ). The median overall survival was 10.5 
months (placebo) and 10.1 months (thalidomide). After adjustment 
for age, sex, and the stratification factors used in the random 
assignment, there was still no difference in overall survival 
(adjusted HR for death = 1.11, 95% CI = 0.94 to 1.32). After 
excluding those patients with ECOG performance status 3, overall 
survival was similar in the two groups (HR for death = 1.10, 95% 
CI = 0.94 to 1.30). Progression-free survival was also similar in the 
two groups (HR for progression or death = 1.07, 95% CI = 0.92 to 
1.24). No differences were observed in the rates of local relapse 
according to treatment allocation (thalidomide vs placebo: 40% vs 
43%) or distant relapse (thalidomide vs placebo: 51% vs 55%). 
Objective tumor response rates were similar in the two groups 
( Supplementary  Table  4 , available online). 
 Because there was a difference in the median length of time on 
the study drug in the two groups, we examined overall survival 
according to the percentage of time on treatment. Among the 300 
patients who took the trial treatment for at least 80% of the time 
they were in the study, overall survival appeared to be worse in the 
thalidomide group than in the placebo group (HR for death = 1.35, 
95% CI = 1.06 to 1.71;  P = .014). Among the 219 patients who 
took their trial treatment for at least 90% of the time, overall sur-
vival was similar in the two groups (HR for death = 1.21, 95% CI 
= 0.92 to 1.60;  P = .18). These results suggest that thalidomide may 
have unexpectedly increased the risk of dying. 
 Clinical outcome differs between patients with limited and 
extensive disease, so we examined the effect of treatment in these 
two groups. The median survival for patients with limited disease 
was 12.1 and 13.1 months in the placebo and thalidomide groups, 
respectively; among patients with extensive disease, the corre-
sponding median survival times were 9.1 and 8.0 months. In an 
exploratory subgroup analysis, there was an interaction between 
disease and treatment ( P = .011). Among patients with limited 
disease, survival was similar (HR for death = 0.91, 95% CI = 0.73 
to 1.15), but in patients with extensive disease, thalidomide was 
associated with a higher rate of death (HR for death = 1.36, 95% 
CI = 1.10 to 1.68) ( Supplementary  Figure  2 , available online). 
Subgroup analyses were not prespeciﬁ ed, so no other factor was 
examined in this way. 
 Toxic Effects 
 There were no substantial differences between the trial groups in 
the incidence of grades 3 and 4 hematological and nonhematologi-
cal adverse effects, although slightly more patients in the thalido-
mide group had rash, constipation, or neuropathy ( Table 2 ). Toxic 
effects reported separately during chemotherapy and maintenance 
are shown in  Supplementary  Table  5 (available online). Although 
there was no difference in adverse effects between treatments dur-
ing chemotherapy, there were more nonhematological toxic effects 
in the thalidomide group during follow-up (risk difference = 6.3%, 
95% CI = 1.4% to 11.2%). Compared with the placebo group, 
there was a twofold increased risk of developing a thrombotic event 
in the thalidomide group (19% [68 of 365] vs 10% [35 of 359]; HR = 
2.13, 95% CI = 1.41 to 3.20;  P < .001). The excess was largely 
attributable to pulmonary emboli and deep vein thromboses (38 vs 
12;  Table 3 ). At 6 months, the estimated risk difference was 9%, 
and it remained largely constant thereafter ( Figure 4 ). These events 
tended to occur while patients were on the study drug because the 
average time on thalidomide was about 7 months. The thromboem-
bolic risk was raised regardless of the ECOG performance score. 
More details are provided in  Supplementary  Table  6 (available 
online). Serious thrombotic events are specified in  Supplementary 
 Tables  6 and  7 and  Supplementary  Figure  3 (available online). Four 
deaths were recorded from myocardial infarction or pulmonary 
embolism, all in the thalidomide group, but with so few events, it 
was not possible to reliably determine whether they were caused by 
thalidomide. 
 Quality of Life 
 Baseline QoL forms were completed by 95% of patients, with 
66% completing forms for at least five time points. There were no 
 Table 1 .  Baseline characteristics * 
 Characteristic
Thalidomide, 
 n  =  365
Placebo, 
n  =  359 
 Age at random assignment 
  ≥ 50 y, No. (%) 344 (94) 332 (92) 
  Median (range), y 65 (38 – 85) 65 (40 – 86) 
 Sex, No. (%) 
  Male 211 (58) 201 (56) 
  Female 154 (42) 158 (44) 
 Women of childbearing 
  potential, No. (%)
8/154 (5) 20/158 (13) 
 Men with a partner of 
  childbearing potential, 
  No. (%)
25/211 (12) 25/201 (12) 
 ECOG performance 
  status, No. (%) 
  0 54 (15) 69 (19) 
  1 203 (56) 203 (57) 
  2 95 (26) 58 (16) 
  3 13 (4) 29 (8) 
 Stage, No. (%) 
  Limited 177 (48) 191 (53) 
  Extensive 188 (52) 168 (47) 
 Alkaline phosphatase, † No. (%) 
  ≤ 1.5 322 (88) 315 (88) 
  >1.5 43 (12) 44 (12) 
 Blood measurements, median 
  (25th – 75th percentile) 
  Sodium, mmol/L 136 (133 – 138) 137 (133 – 140) 
  Albumin, g/L 38 (34 – 41) 39 (34 – 42) 
 White blood cell count, ×10 9 /L  9.6 (8.0 – 12.2) 9.7 (7.9 – 12.4) 
  Lactate dehydrogenase, U/L 502 (386 – 724) 493 (359 – 698) 
 *  ECOG  =  Eastern Cooperative Oncology Group. 
 †  Times upper limit of normal range. 
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 Figure 1 .  CONSORT diagram of the trial. *The 
ineligible patients were included because 
they were already randomly assigned and are 
few in number. SCLC = small cell lung cancer; 
GFR = glomerular ﬁ ltration rate. 
substantial differences in QoL scores at baseline (each factor was 
based on a scale of 0 – 100). During the study, the mean differences 
in scores between treatment groups remained similar over time 
(except for peripheral neuropathy). Thalidomide was associated 
with less insomnia, pain, and diarrhea, and more dyspnea, consti-
pation, and peripheral neuropathy (most of which were expected). 
The differences in mean scores were not large:   10.0 (insomnia), 
  3.2 (diarrhea),   4.3 (pain), 5.3 (dyspnea), 10.6 (constipation), 
and 6.1 (neuropathy at 24 weeks after random assignment). The 
effects were similar when the data were restricted to the mainte-
nance treatment period, that is, after chemotherapy ended. Details 
are shown in  Supplementary  Tables  8 – 10 (available online). We 
also examined whether thalidomide had a beneficial effect on 
weight during chemotherapy, but there was no evidence of this: 
the mean increase in weight from baseline to the end of chemo-
therapy was 1.8 kg in both treatment groups. 
 Discussion 
 To our knowledge, this is the first full randomized phase III 
trial to evaluate an anti-angiogenic agent for the treatment of 
SCLC and the largest treatment trial conducted in this disease 
to date. Despite preliminary promising evidence and biological 
plausibility, thalidomide was not associated with a survival 
724 patients randomly assigned 
Thalidomide: 365 patients Placebo: 359 patients 
Ineligible (n = 2):
concurrent malignancy (n = 1);
GFR too low (n = 1)
Ineligible (n = 6):
not SCLC (n = 2);
prior chemotherapy (n = 1);
prior thrombotic event (n = 1);
GFR too low (n = 2)
Followed-up: 365 patients Followed-up: 359 patients
Never started drug: 15
Started, but no date: 4
Missing data: 2
Reason for stopping:
Still on drug: 2
Completed 24 months: 8
Protocol toxicity: 39
Clinical/patient non-protocol
other toxicity: 53
Clinical morbidity: 43
Patient request (not toxicity): 31
Progressive disease: 69
Death: 64
Unavailable: 14
Other: 21
Never started drug: 13
Started, but no date: 8
Missing data: 2
Reason for stopping:
Still on drug: 4
Completed 24 months: 12
Protocol toxicity: 14
Clinical/patient non-protocol
other toxicity: 26
Clinical morbidity: 40
Patient request (not toxicity): 36
Progressive disease: 107
Death: 42
Unavailable: 23
Other: 32
Analysis: 365 patients * Analysis: 359 patients *
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benefit, but it did increase the risk of developing a thrombotic 
event. 
 Three previous small studies of thalidomide in SCLC showed 
promising results ( 15 – 17 ). Two were single-arm phase II studies: 
Dowlati et al. ( 15 ) (thalidomide administered as maintenance 
therapy at a dose of 200 mg, n  =  30) and Lee et al. ( 17 ) (thalido-
mide given concurrent with chemotherapy at a dose of 100 mg, 
n  =  25) with 1-year survival rates of 52% and 46%, respectively, 
which were greater than the expected rate of 20% – 30%. The third 
was a small, placebo-controlled, randomized study by Pujol et al. 
( 16 ) (thalidomide given as maintenance therapy at a dose of 400 
mg [n  =  49 thalidomide and n  =  43 placebo]) in which the 1-year 
survival rates were 49% in patients receiving thalidomide vs 30% 
in patients receiving placebo, and the median survival times were 
11.7 and 8.7 months, respectively. The chance of dying was 
reduced by a quarter (HR for death  =  0.74, 95% CI  =  0.49 to 1.12), 
which was not statistically signiﬁ cant ( P  =  .16). Taken together, the 
results from these studies suggested that thalidomide could have a 
substantial survival beneﬁ t in patients. 
 In contrast to previous small studies, the results of this large 
randomized trial with a control group showed that thalidomide 
was not associated with any beneﬁ t on overall survival or pro-
gression-free interval. The study was large enough to exclude 
any clinically important beneﬁ t of thalidomide. The objective 
response rates to chemotherapy, progression-free interval, and 
overall survival were consistent with previous studies in this 
patient group. It is unlikely that the lack of effect for thalidomide 
was due to poor compliance because approximately 70% of 
patients took their trial treatment for at least half the time they 
were in the study. In fact, the median duration of the study treat-
ment (about 7 months) was longer than that observed in the 
study by Pujol et al. ( 16 ) (4.5 months). We also examined the 
treatment effect in compliers (as deﬁ ned in the “Results”) and 
found no evidence of a survival advantage. The lack of an effect 
on survival associated with thalidomide treatment was also 
observed in a large, double-blind, placebo-controlled trial of 722 
patients with NSCLC ( 33 ), which was conducted by our group at 
about the same time (overall survival: HR  =  1.13, 95% CI  =  0.97 
to 1.32). 
 It is possible that the 200-mg maintenance thalidomide dose we 
used in our study was too low [Pujol et al. ( 16 ) used 400 mg]. 
However, the total dose administered to patients in the current 
study was broadly similar to that administered in the study by 
Pujol et al. because compliance was better and because many 
patients in the previous study required dose reduction. Moreover, 
there is no evidence to support a dose – response relationship for 
thalidomide in the treatment of multiple myeloma or solid tumors 
( 34 , 35 ). In multiple myeloma, thalidomide at 400 mg/d with che-
motherapy is associated with an improved survival rate at 5 years 
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 Figure 3 .  Kaplan – Meier analysis of outcomes according to treatment 
group.  A ) Overall survival. Thalidomide: 329 deaths, median  =  10.1 
months, and 1- and 2-year survival rates were 37% and 13%, respectively. 
Placebo: 320 deaths, median  =  10.5 months, and 1- and 2-year survival 
rates were 41% and 14%, respectively. Hazard ratio  =  1.09 (95% conﬁ -
dence interval [CI]  =  0.93 to 1.27),  P  =  .28 (two-sided log-rank test).  B ) 
Progression-free interval. Thalidomide: 337 events, median  =  7.6 months, 
and 1- and 2-year rates were 22% and 7%, respectively. Placebo: 330 
events, median  =  7.6 months, and 1- and 2-year rates were 24% and 8%, 
respectively. Hazard ratio  =  1.07 (95% CI  =  0.92 to 1.24),  P  =  .39 (two-sided 
log-rank test). 
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( 12 ). A multicenter, prospective, randomized trial testing thalido-
mide 100 or 400 mg/d in patients with refractory or relapsed 
multiple myeloma demonstrated similar 1-year survival rates, but 
low-dose thalidomide was better tolerated with less somnolence, 
constipation, and peripheral neuropathy ( 34 ). Although the three 
previous studies in SCLC used different thalidomide doses, the 
1-year survival rates were similar ( 15 – 17 ). Studies in which a 
higher thalidomide dose was used to treat SCLC or breast cancer 
reported substantial toxicity and poorer compliance ( 15 , 35 , 36 ). 
The dose used in this study was one with proven biological effects 
in other settings but with a tolerable toxicity proﬁ le. If a much 
higher dose were used in our trial, it is likely that more patients 
would have had difﬁ culty in continuing to the maintenance phase 
of therapy. 
 It is important to consider whether any possible beneﬁ t of thali-
domide was outweighed by a negative effect on chemotherapy dose 
intensity. We observed no difference in the number of cycles and 
dose reductions or delays in the thalidomide and placebo groups. 
Furthermore, there was no increase in chemotherapy-associated 
adverse effects, including myelosuppression and febrile neutro-
penia, in the thalidomide arm. Although thalidomide did not 
adversely affect overall QoL or tumor response, the reduced com-
pliance with thalidomide compared with placebo suggested poorer 
tolerability, which was not fully captured using our toxicity and 
QoL measurements. 
 The main adverse effect associated with thalidomide was a 
doubling of the risk of developing a thrombotic event, which is 
consistent with other studies ( 37 , 38 ). The Independent Data 
Monitoring Committee observed this doubling during the course 
of the trial, and the patient information sheet was changed 
accordingly. Patients already on study were informed of the risks 
and reconsented to continuing the study drug. Thrombotic 
events were treated using standard anticoagulants. There was no 
evidence of a higher risk of recurrent or refractory thromboses. 
 There was evidence that thalidomide was associated with a 
poorer overall survival among patients with extensive-stage disease. 
Overall, there was no difference between the trial groups in the 
number of deaths reported due to causes other than lung cancer 
( Supplementary  Table  3 , available online). Three possible reasons 
for poorer survival in patients with extensive disease who were 
treated with thalidomide were the following: 1) thalidomide accel-
 Table 2 .  Reported grade 3 or 4 toxic effects (except thrombotic 
events) * 
 Type of toxic effect
Thalidomide, 
n  =  365
Placebo, 
n  =  359 
 Hematological, No. (%) 
  Anemia 44 (12) 34 (9) 
  Leucopenia 69 (19) 59 (16) 
  Neutropenia 171 (47) 179 (50) 
  Thrombocytopenia 35 (10) 39 (11) 
  Any (each patient 
 counted once), No. (%)
190 (52) 192 (53) 
  Absolute risk difference 
  (95% CI) † 
  1.4% (  8.7 to 5.8), 
 P  =  .70 
 Nonhematological, No. (%) 
  Constipation 37 (10) 10 (3) 
  Diarrhea 8 (2) 11 (3) 
  Nausea 9 (2) 9 (3) 
  Vomiting 4 (1) 14 (4) 
  Mucositis/stomatitis (oral) 3 (1) 4 (1) 
  Anorexia 6 (2) 7 (2) 
  Infection (not neutropenic) 15 (4) 13 (4) 
  Infection (neutropenic) 27 (7) 21 (6) 
  Dizziness 15 (4) 16 (4) 
  Somnolence/drowsiness 14 (4) 15 (4) 
  Neuropathy/sensory 22 (6) 8 (2) 
  Dry skin 5 (1) 2 (1) 
  Rash 16 (4) 1 (<1) 
  Renal 3 (1) 2 (1) 
  Other 48 (13) 50 (14) 
  Any (each patient 
  counted once), No. (%)
148 (41) 123 (34) 
  Absolute risk difference 
  (95% CI) † 
6.3% (  0.7 to 13.3), 
 P  =  .08 
  Any toxic effect, No. (%) 251 (69) 239 (67) 
  Absolute risk difference 
  (95% CI) † 
2.2% ( – 4.6 to 9.0), 
 P  =  .53 
 *  The table is based on the maximum grade observed during chemotherapy or 
follow-up.  P values (two-sided) were calculated using   2 test. 
CI  =  confidence interval. 
 †  Thalidomide minus placebo. 
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 Figure 4 .  Kaplan – Meier analysis of developing any thrombotic event 
according to treatment group. Hazard ratio  =  2.13, 95% conﬁ dence 
interval  =  1.41 to 3.20;  P < .001 (two-sided log-rank test). 
 Table 3 .  Type of first thrombotic event that was observed during 
chemotherapy or follow-up * 
 Event type Thalidomide Placebo 
 Pulmonary embolism 25 7 
 Deep vein thrombosis 13 5 
 Embolus 7 4 
 Transient ischemic attack 6 1 
 Cerebrovascular accident 9 8 
 Myocardial infarction 5 4 
 Other 3 6 
 Total 68 35 
 *  The table shows the number of patients and is based on any severity 
(eight suspected cases are included). 
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erated lung cancer progression in patients with extensive disease, 2) 
some of the deaths were incorrectly recorded as being due to lung 
cancer but were due to a thrombotic event or another adverse 
effect, or 3) chance alone. Bone or brain CT scans are not routinely 
performed in the United Kingdom, so it is possible that our less 
stringent staging criteria may have led to some patients with 
asymptomatic metastatic disease to be classiﬁ ed as having limited 
disease. However, the proportion of patients with brain scans 
should have been similarly distributed between the trial arms due 
to randomization. 
 The lack of a beneﬁ t using thalidomide is consistent with other 
studies of anti-angiogenic treatments in SCLC. A randomized 
phase II study using vandetanib (ZD6474), a VEGF receptor 
tyrosine kinase inhibitor, as maintenance after chemotherapy in 
SCLC ( 39 ) showed no beneﬁ t in terms of overall survival or 
progression-free interval when compared with placebo. Two ran-
domized phase II studies ( 40 , 41 ) using bevacizumab did not 
achieve the outcomes required to progress to phase III trials. 
Nevertheless, caution needs to be exercised when interpreting our 
ﬁ ndings. Unlike the results reported with bevacizumab, sorafenib, 
and cediranib in NSCLC, we did not observe an increase in 
response rates. It is possible that the 200-mg dose used in the cur-
rent study was too low compared with the trial reported by Pujol 
et al. ( 16 ), which used 400 mg. 
 Together, these results suggest that targeting anti-angiogenesis 
in SCLC may not work as well as in multiple myeloma or colorec-
tal cancer, perhaps because of differences in the angiogenic path-
ways involved in SCLC. There is also emerging evidence suggesting 
that anti-angiogenic agents may work better with some chemo-
therapy agents than others ( 42 , 43 ). 
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